Vivalis signs up Japanese partner for vaccine technology

Vivalis SA of Nantes France has signed two commercial license agreements with the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) of Kumamoto, Japan. The agreements cover Vivalis’ proprietary EB66 cell line, for the production of several veterinary and human vaccines, including Vaccinia virus-based recombinant human vaccines and inactivated and live viral human vaccines.

“This agreement with Kaketsuken, a leading company in the fields both human and animal vaccines in Japan, constitutes an additional and significant industrial endorsement of Vivalis EB66 technology,” said Franck Grimaud, Vivalis CEO. “With a portfolio of 21 licenses, the EB66 cell line is reinforcing its position as a new standard cell substrate for the manufacturing of biological products.”